THE TAPE
ADPT · Biotechnology · $4.4B

Adaptive Biotechnologies Corporation Common Stock

$27.87▼ −4.03%
Last close
Relative strength
97RS
of 99, against every stock▲ +8 on the month
Powering up
Developing
+78.5%
six months against Biotechnology
52-week range
−13.5%
from the high
$12.00$32.21
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 30, revenue −11% on a year ago
Why it is on no screen

ADPT is off the screens on one check: shallow enough.

A base has formed19.6 weeks, from 12.00 to 19.80.
Long enough to count19.6 weeks against 3 needed.
Shallow enough39.4% deep against 35% allowed.
Close to its pivot+40.8% from the pivot; listed down to -20%.
Relative strengthRS 97 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$26.92
-3.4% · tested 3× · last 32 sessions ago
Resistance above
$28.85
+3.5% · tested 3× · last 13 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Adaptive Biotechnologies Corporation Common Stock is not on any of the screens right now. Its relative strength rating is 97, and it sits in Biotechnology.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+12.8%
Three months against its industry
+21.0%
Six months against its industry
+78.5%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 8.9% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$298.0M
-10.7% year on year
Operating margin
-16.2%
Net margin
-23.7%
Free cash flow
$-8.8M
-0.2% of market cap
Price to sales
14.9×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Revenue is falling but the business still generates cash.
Revenue
$83.9M
+17.3% QoQ · -10.7% YoY
Gross margin
—
Net income
$2.9M
Positive
Free cash flow
$7.7M
Cash generating

What the numbers say

  • Weak: Revenue -10.7% year over year, +17.3% on the quarter
  • Net income $3M on an operating loss of $457K: below the line, not operations
  • Good: Cash generating: operating cash flow $10M, free cash flow $8M
  • Weak: Share count +14.5% in a year: dilution
  • Good: Net cash $76M · cash $76M
Revenue by quarter
Free cash flow
Net income
shares +14.5% in a year · net cash $75.6M

What is not obvious

  • Weak: Cash flow quality: operating cash flow $10M included a $7M deferred-revenue inflow; $3M without it. Customers paid ahead of delivery
  • Weak: Stock compensation $10M added back, 108% of operating cash flow; -$781K after it
  • Weak: Interest $503K a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -10.7% year over year, +17.3% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 4 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added, 2 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-10
+8.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-06
above 20d & 50d on 1.8x volume at 26.83
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Reported resultsFiling · 2026-11-05
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-11-03
reports 2026-11-04 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
GappedTape · 2026-11-03
-5.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-31
above 20d & 50d on 2.0x volume at 26.64
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-10-31
-5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-28
+5.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
85
$63,228,624 total

Sold: RUBINSTEIN JULIE, BOBULSKY SUSAN, LO FRANCIS, OWEN KATEY EINTERZ, HERSHBERG ROBERT, ROBINS CHAD M, NEUPERT PETER M, ROBINS HARLAN S, BENZENO SHARON, GRIFFIN MICHELLE RENEE.

Not counted above: 59 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-06 RUBINSTEIN JULIE · President and COOoption exercise11,881$144,235
2026-11-06 RUBINSTEIN JULIE · President and COOsell8,400$229,488
2026-11-06 RUBINSTEIN JULIE · President and COOsell3,481$97,050
2026-11-05 RUBINSTEIN JULIE · President and COOoption exercise11,881$144,235
2026-11-05 RUBINSTEIN JULIE · President and COOsell5,926$154,669
2026-11-05 RUBINSTEIN JULIE · President and COOsell5,455$146,630
2026-11-05 RUBINSTEIN JULIE · President and COOsell500$13,850
2026-11-04 RUBINSTEIN JULIE · President and COOoption exercise11,881$144,235

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy2
Buy6
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Adaptive Biotechnologies Corporation Common Stock (ADPT) — The Tape